MedTrace Logo

Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma

NCT03738111 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-09-25

No results posted yet for this study

Summary

This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

TG02 Citrate

TG02 citrate capsules

Sponsors & Collaborators

  • China Oncology Focus Limited

    collaborator OTHER

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-31
Primary Completion
2021-08-31
Completion
2021-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03738111 on ClinicalTrials.gov